Two patients with severe aplastic anaemia received bone-marrow transplants from unrelated donors selected for HLA compatibility. Graft-versus-host disease occurred in both patients but responded to treatment. Both patients had stormy courses after grafting, but subsequently their conditions improved, and one was not receiving any treatment at follow-up after day 330 while the other had mild chronic graft-versus-host disease at day 150.
who have serious infectious complications. Bone-marrow transplantation from histocompatible unrelated donors or from mismatched related donors offers an alternative form of treatment. We report here the clinical courses of two patients with severe aplastic anaemia who received transplants from unrelated donors selected for HLA compatibility.
Case reports CASE 1
A 19-year-old girl student presented in March 1981 with a short history of easy bruising after an episode of non-A non-B hepatitis one month before. Blood count, bone-marrow aspirate, and a trephine biopsy specimen showed that she had severe aplastic anaemia (haemoglobin concentration 6-4 g/dl, reticulocytes <0.1%; white cell count 0-2 x 109/1, no neutrophils; platelets 10 x 109/1; bone marrow >80% of cells non-myeloid). She was an only child and her parents were not histocompatible. She In January he was transferred to Hammersmith Hospital for bonemarrow transplantation from a donor (donor 9). Immunosuppression was given with antilymphocyte globulin (Merieux) on days -7, -5, and -3; procarbazine 12-5 mg/kg/day on days -6, -4, and -2; and cyclophosphamide 50 mg/kg/day on days -5 to -2 inclusive. He was also given intravenous cyclosporin A 5 mg/kg twice daily on days -4 to -1 inclusive, when he was switched to oral cyclosporin A 6-25 mg/kg twice daily; this was discontinued at day 10 because of deteriorating renal function. On 24 February (day 0) he received 2 6 x 108 nucleated cells/kg body weight aspirated from the marrow of donor 9. Neutrophils appeared in the peripheral blood at day 8, but he required red-cell and platelet support until day 42. Major complications after grafting included hepatorenal failure, which required haemodialysis for 21 days, and acute skin graft-versus-host disease (grade III at day 6), which responded to high-dose methylprednisolone.
He was discharged at day 65 with normal blood counts. He was not receiving cyclosporin A because reintroduction of the drug had produced an allergic reaction. On On their first visit the donors were seen by a member of the transplant team and asked if they still felt that they would like to give marrow and the nature of the procedure was explained to them. They were asked if they had any history of illness and to provide the name and address of their general practitioner. None of the potential donors screened in this way expressed any doubts about their willingness to proceed as a donor. Once it became established that full histocompatibility was present the compatible donor was asked to attend for further explanation of the procedure, for medical examination by a physician, and for blood count, chest radiography, and electrocardiography. The patient's general practitioner was contacted for information about his history and exposure to drugs. One of the potential donors had a history of depression for which prothiaden had been given but discontinued three months previously. The general practitioner expressed some concern about using this particular donor.
After discussion with other colleagues and the general practitioner we felt that to reject a donor on the grounds of previous depression would be more 
Discussion
Successful bone-marrow transplantation from an unrelated donor has been reported for treatment of acute myeloid leukaemia in remission.7 It has not been reported before in the treatment of severe aplastic anaemia with evidence of sustained engraftment, though unsuccessful attempts have been made.8 9 Both the patients reported on here received many blood transfusions. Multiple blood transfusions are associated with an increased risk of graft rejection in aplastic anaemia,'0 though possibly the use of cyclosporin A permitted engraftment in our patients despite this problem." Graft-versus-host disease occurred in both patients but in each case the acute episodes responded to treatment. The man had chronic graft-versus-host disease of the skin, which seemed to respond to prednisone and azathioprine. Both patients had stormy courses after grafting. Some of the infectious complications in the woman may have been related to the delay in bone-marrow transplantation since she had proved septicaemia before starting. Herpes zoster infections are common after grafting. ' Introduction Pyoderma gangrenosum has been rarely associated with various haematological malignancies. We report an association with primary thrombocythaemia.
Case report
A 54-year-old Caucasian man presented with a four-week history of increasing ulceration on the outer aspect of the left lower leg. There was no history of bowel disease, varicose veins, or arthritis, and peripheral pulses in the legs were strong. Results of investigations at this time were: haemoglobin 15 1 g/dl, red cell count 6-68 x 1012/1, packed cell volume 0 464, white cell count 16 4 x 109/1, and platelets 1210 x 109/1; leucocyte alkaline phosphatase activity was normal. The
